Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data

Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data

Background Liver injury has been documented independently in novel coronavirus disease 2019 (COVID-19) patients and patients treated with lopinavir-ritonavir. Objective to investigate the drug-induced liver injury associated with lopinavir-ritonavir among the patients with COVID-19. Methods We condu...

Full description

Bibliographic Details
Main Authors: Barnes, E.L (Author), Kinlaw, A.C (Author), Li, X. (Author), Moon, A.M (Author), Tang, H. (Author), Wang, T. (Author), Yang, J.Y (Author), Zhou, L. (Author)
Format: Article
Language:English
Published: Springer Science and Business Media Deutschland GmbH 2021
Subjects:
adult
Adverse Drug Reaction Reporting Systems
adverse outcome
aged
Aged
anti human immunodeficiency virus agent
Anti-HIV Agents
Article
Chemical and Drug Induced Liver Injury
complication
coronavirus disease 2019
COVID-19
drug combination
Drug Combinations
drug effect
drug efficacy
drug response
drug safety
drug surveillance program
drug-induced liver injury
FAERS
female
Female
Food and Drug Administration
HIV Infections
human
Human immunodeficiency virus infection
Humans
hydroxychloroquine
injury severity
Liver injury
lopinavir
Lopinavir
lopinavir plus ritonavir
Lopinavir-ritonavir
lopinavir-ritonavir drug combination
major clinical study
male
Male
middle aged
Middle Aged
Novel coronavirus disease 2019
remdesivir
risk factor
ritonavir
Ritonavir
toxic hepatitis
United States
United States Food and Drug Administration
virology
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items